Abstract:Previous studies have examined the effects of metabolic syndrome (MetS) rather than its severity on race and ethnic disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). We used the MetS severity score, a validated sex-race-ethnicity-specific severity measure, to examine the effects of race/ethnicity on the association between MetS severity and MASLD. This study included 10,605 adult participants from the Third National Health and Nutrition Examination Survey. The MASLD diagnosis was based on ultrasound findings in patients without excessive alcohol intake or other liver diseases. MetS severity Z-scores were calculated and stratified into four categories low (1 st -50 th ), moderate (>50 th -75 th ), high (>75 th -90 th ), and very high (>90 th +)]. Multivariable adjusted logistic regression models with complex survey methods were used to test the effect of MetS severity on MASLD. The age-adjusted MASLD prevalence was 17.4%, 25.7%, 42.5, and 54.9% in adults with mild, moderate, high, and very high MetS severities, respectively (P-trend <0.001). MetS severity was significantly higher in patients with MASLD than in those without [mean percentile 60 th vs. 44 th , P<0.001]. Among patients with MASLD, Mexican-American and Black non-Hispanic females had significantly higher age-adjusted MetS severity (68 th and 61 st , respectively) than White non-Hispanic females 54 th , while Black non-Hispanic males had significantly lower MetS severity (56 th ) than White non-Hispanic males (70 th ) (P-Interaction = 0.02). Adults with high and very high MetS severity had 2.27 (95% CI:1.70 to 3.03) and 3.12 (95% CI:2.20 to 4.42), respectively, higher adjusted odds of MASLD than those with mild MetS severity. Racial/ethnic disparities in MetS severity play a pivotal role in the risk of MASLD. Our findings highlight the potential clinical utility of the MetS severity score in identifying at-risk individuals, which will help guide targeted prevention and tailoring management strategies to mitigate the MASLD burden.

S1944 Recruitment of Minority Patients in Metabolic Dysfunction-Associated Steatotic Liver Disease Clinical Trials

Manifestation and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Predominately African American Population at a Multi-Specialty Healthcare Organization

Disparate outcomes in Hispanic patients with metabolic dysfunction-associated steatotic liver disease/steatohepatitis and type 2 diabetes: Large cohort study

Disparities among ethnic groups in mortality and outcomes among adults with MASLD: A multicenter study

Disparities in screening and risk stratification for hispanic adults with metabolic dysfunction-associated steatotic liver disease

S1883 Evaluating Differences in Screening Between Pediatric and Adult Patients for Development of Metabolic Dysfunction-Associated Steatotic Liver Disease at an Academic Primary Care Clinic

Disparities in Liver Transplantation for Nonalcoholic Steatohepatitis in Women

Intervening on Metabolic Dysfunction-Associated Steatotic Liver Disease in Latino/a and Black Patients with Diabetes: A Feasibility Pilot

Waitlist and transplant outcomes in patients with metabolic dysfunction-associated steatotic liver disease and autoimmune hepatitis

S1880 Evaluating Liver Transplant Referral Rates and Disparities Among Cirrhotic Patients: A Study in the Hispanic Population

S207 Differences In Clinical Outcomes Between Acute Pancreatitis Caucasian, African American, and Asian Population With Metabolic Dysfunction-Associated Steatotic Liver Disease

The impact of metabolic syndrome severity on racial and ethnic disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease

Disease Progression for Histologic Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Real-World: A Nationwide US Study

Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease

Short- and Long-Term Outcomes for Ethnic Minorities in the United States After Liver Transplantation: Parsing the Hispanic Paradox

Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease: Current Progress and Challenges

S2050 Missed Opportunities to Screen for Fatty Liver: Improving Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Screening Through a Quality Assessment and Quality Improvement Project

Waitlisting and liver transplantation for MetALD in the United States: An analysis of the UNOS national registry

Incretin-based investigational therapies for the treatment of MASLD/MASH

S1910 Differential Effect of Cardiometabolic Risk Factors on Mortality in US Adults With Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)

Patient-Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease